PCIA
IBRX icon

Prime Capital Investment Advisors’s ImmunityBio IBRX Stock Holding History

Prime Capital Investment Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$145K Buy
+18,870
New +$129K ﹤0.01% 996

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Prime Capital Investment Advisors's IBRX Position: Q1 2026 in Review

Prime Capital Investment Advisors opened a new position in ImmunityBio (IBRX) in Q1 2026: 18,870 shares worth $145K. The stake represents ﹤0.01% of the portfolio and ranks #996 among its holdings.

386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • Prime Capital Investment Advisors held 18,870 shares of ImmunityBio worth $145K as of Q1 2026.
  • ImmunityBio was a new Prime Capital Investment Advisors position in Q1 2026.
  • ImmunityBio made up ﹤0.01% of Prime Capital Investment Advisors's portfolio in Q1 2026, its #996 holding.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Prime Capital Investment Advisors's 13F filing for Q1 2026, filed 8 May 2026.